Clinical Advisory Board
James Merson, Ph.D.
Dr. Merson is a R&D consultant in the areas of vaccines (prophylactic and therapeutic), infectious diseases (small and macromolecule) and immuno-oncology, advising VC companies and is a member of several Scientific Advisory and Company Boards. Most recently, he was CSO of Vaccine Immunotherapeutics at Pfizer and has 29 years of broad and deep Pharm R&D experience. He is passionate about applying state-of-the-art science and technologies to discover and develop differentiated medicines and vaccines. Responsible for establishing 3 R&D units in Pfizer with the most recent being the Pfizer Board endorsed Vaccine Research via the integration of 3 acquired companies, PowderMed, Coley Pharmaceuticals and Wyeth, resulted in an innovative portfolio of prophylactic and therapeutic vaccines combined with immunomodulators, to significantly improve the prevention and treatment of viral and bacterial diseases, dyslipidemia, asthma, cancer, Alzheimer’s disease, and smoking cessation. He was also responsible for implementing collaborations with Western Oncolytics and IGNITE Immunotherapy to generate novel oncolytic viruses for combination with checkpoint inhibitors for the treatment of cancer.
Mai H. Le, M.D.
Mai is a strategic advisor for biotechnology companies with a focus in oncology and immunotherapy. Dr. Le has over 8 years of oncology drug development experience that includes small molecules, biologics, medical devices and companion diagnostics strategy. She previously served as a medical director at Calithera Biosciences, Plexxikon Inc., Onyx Pharmaceuticals and Proteolix, Inc (acquired by Onyx Pharmaceuticals), and most recently, as the Chief Medical Officer at OncoSec Medical, Inc. Dr. Le obtained a medical degree from the University of Rochester School of Medicine and Dentistry and trained in Laboratory Medicine at University of California, San Francisco.
Boris Minev, MD, Ph.D.
Boris is currently the Director of Immunotherapy and Translational Oncology at Genelux Corporation studying the phenotype and characterization of metastasized cancer cells circulation. Dr. Minev previously worked as the Principal Investigate at the Laboratory of Tumor Immunology and Immunotherapy at the Moores UCSD Cancer Center. Dr. Minev has an extensive experience with cancer vaccines, having worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine).